For the quarter ending 2025-09-30, DMAAR has $237,632,428 in assets. $7,356,611 in debts.
| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash | 717 | - | ||
| Prepaid expenses and other current assets | 27,479 | 48,904 | ||
| Cash | - | 822 | ||
| Total current assets | 28,196 | 49,726 | ||
| Deferred offering costs | - | 0 | ||
| Cash and investments held in trust account | 237,604,232 | 235,155,966 | ||
| Total assets | 237,632,428 | 235,205,692 | ||
| Promissory note related party-Related Party | - | 0 | ||
| Accounts payable and accrued expenses | 302,623 | 147,453 | ||
| Accrued offering costs | 153,988 | 153,988 | ||
| Total current liabilities | 456,611 | 301,441 | ||
| Deferred underwriting fee payable | 6,900,000 | 6,900,000 | ||
| Total liabilities | 7,356,611 | 7,201,441 | ||
| Ordinary shares subject to possible redemption, 23,000,000 shares at redemption value of 10.30 and 0 per share as of september 30, 2025 and december 31, 2024, respectively | 237,604,232 | 235,155,966 | ||
| Ordinary shares, 0.0001 par value 220,000,000 shares authorized 10,517,143 and 9,857,143 shares issued and outstanding, excluding 23,000,000 and 0 shares subject to redemption as of september 30, 2025 and december 31, 2024, respectively | 1,052 | 1,052 | ||
| Share subscription receivable | 608,822 | 695,825 | ||
| Additional paid-in capital | - | 0 | ||
| Accumulated deficit | -6,720,645 | -6,456,942 | ||
| Total shareholders deficit | -7,328,415 | -7,151,715 | ||
| Total liabilities and shareholders deficit | 237,632,428 | 235,205,692 | ||
Drugs Made In America Acquisition Corp. (DMAAR)
Drugs Made In America Acquisition Corp. (DMAAR)